United Therapeutics (NasdaqGS:UTHR) Q4 2025 Earnings call February 25, 2026 09:00 AM ET Company ParticipantsAshish Varma - Group Internal Audit - AI Initiatives ManagerDewey Steadman - Head of Investor RelationsLeigh Peterson - EVP of Product Development and XenotransplantationMartine Rothblatt - Chairperson and CEOMichael Benkowitz - President and COOConference Call ParticipantsJoseph Thome - Managing Director and Senior Research AnalystRoanna Ruiz - Senior Research AnalystRoger Song - Senior Equity Resear ...

United Therapeutics (NasdaqGS:UTHR) Q4 2025 Earnings call February 25, 2026 09:00 AM ET Company ParticipantsAshish Varma - Group Internal Audit - AI Initiatives ManagerDewey Steadman - Head of Investor RelationsLeigh Peterson - EVP of Product Development and XenotransplantationMartine Rothblatt - Chairperson and CEOMichael Benkowitz - President and COOConference Call ParticipantsJoseph Thome - Managing Director and Senior Research AnalystRoanna Ruiz - Senior Research AnalystRoger Song - Senior Equity Resear ...

United Therapeutics (NasdaqGS:UTHR) Q4 2025 Earnings call February 25, 2026 09:00 AM ET Speaker5Please also know today's event is being recorded. At this time, I'd like to turn the webcast over to Dewey Steadman, Investor Relations Manager at United Therapeutics.Speaker1Thank you, Jamie. Good morning. It is my pleasure to welcome you to the United Therapeutics Corporation 4th quarter 2025 corporate update webcast. Remarks today will include forward-looking statements representing our expectations or beliefs ...

United Therapeutics Corporation Fourth Quarter 2025 Corporate Update February 25, 2026 2 INTRODUCTION Safe Harbor Statement Dr. Martine Rothblatt Michael Benkowitz All statements in this presentation are made as of February 25, 2026. We undertake no obligation to publicly update or revise these statements, whether as a result of new information, future events, or otherwise. Statements included in this presentation that are not historical in nature are "forward-looking statements" within the meaning of the P ...

Exhibit 99.1 SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., February 25, 2026: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2025. Full year 2025 revenues rose to a record $3.18 billion, reflecting 11% growth over 2024. "As we close out another remarkable year with record total revenue for the fourth year in a row, I extend my thanks to our Unitherians whose unwavering commitment to innova ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) (Address of Principal Executive Offices) ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2025. Full year 2025 revenues rose to a record $3.18 billion, reflecting 11% growth over 2024. "As we close out another remarkable year with record total revenue for the fourth year in a row, I extend my thanks to our Unitherians whose unwavering commitment to innovation. ...

Core Viewpoint - Analysts forecast that United Therapeutics (UTHR) will report quarterly earnings of $6.78 per share, reflecting a year-over-year increase of 9.5%, with anticipated revenues of $805.31 million, marking a 9.4% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate for the quarter has been revised downward by 0.2% over the past 30 days, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Revenue Estimates - Analysts estimate 'Revenues- Adcirca' will reach $4.62 million, a decrease of 1.6% from the year-ago quarter [5]. - The average prediction for 'Revenues- Orenitram' is $121.24 million, indicating a year-over-year increase of 12.5% [5]. - The consensus for 'Revenues- Other products' stands at $5.10 million, reflecting a year-over-year decline of 7.3% [5]. - 'Revenues- Remodulin' is expected to be $131.46 million, showing a decrease of 2.3% year over year [6]. - 'Revenues- Tyvaso' is projected to reach $488.25 million, indicating a year-over-year increase of 17.4% [6]. - 'Revenues- Unituxin' is expected to be $51.29 million, suggesting a significant decline of 24% year over year [6]. - 'Revenues- Nebulized Tyvaso' is forecasted at $144.35 million, reflecting a slight increase of 1.2% from the prior year [7]. - 'Revenues- Tyvaso DPI' is expected to reach $313.30 million, indicating a year-over-year increase of 14.7% [7]. - 'Revenues- United States' is projected to be $753.92 million, reflecting a change of 6.8% from the prior-year quarter [7]. - 'Revenues- Rest-of-World' is estimated at $28.71 million, suggesting a year-over-year decline of 4.9% [8]. Stock Performance - Over the past month, shares of United Therapeutics have returned +1.8%, contrasting with the Zacks S&P 500 composite's -0.8% change [8]. - Currently, UTHR holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the overall market in the near future [8].

Core Insights - The article discusses United Therapeutics (UTHR) and its position in the pulmonary diseases market, indicating a growing company with a strong franchise [1]. Group 1 - The author has previously rated United Therapeutics as a hold, reflecting a cautious outlook on the stock's performance [1]. - The investment approach is described as a learning process, emphasizing that both successes and failures contribute to valuable lessons [1]. - The author has focused research on healthcare stocks for approximately five years, indicating a specialized knowledge in this sector [1].

Summary of 3D Systems Conference Call Company Overview - **Company**: 3D Systems - **Industry**: 3D Printing and Additive Manufacturing Key Points Company Transformation - 3D Systems has undergone significant changes over the past five years, focusing on core technologies in industrial and healthcare markets while divesting non-core businesses [4][5] - The company has divested businesses related to digital manufacturing that were not aligned with its core focus on 3D printing [5][6] Market Conditions - The 3D printing industry has experienced volatility, particularly post-pandemic, with initial growth followed by a slowdown due to inflation and economic uncertainty [9][10] - Customers have been cautious with capital spending, impacting demand for 3D printing solutions [10][11] Healthcare Solutions - Healthcare solutions account for approximately 40%-46% of revenues, with a split between orthopedic (MedTech) and dental applications [12][13] - Orthopedic-related revenue is stable and growing, while dental revenue has shown volatility but is diversifying into dentures and other products [14][15] - The dental market represents a significant opportunity, with over 60 million denture wearers in the U.S. and an addressable market of $80 million annually for recurring revenue [25][26] Competitive Landscape - 3D Systems faces competition in the dental market but believes its product quality and performance are superior [30][31] - The company is also expanding into regenerative medicine, with a partnership to develop 3D-printed human lungs, which could be a transformative opportunity [37][39] Industrial Sector - The industrial segment, particularly aerospace and defense, has been a bright spot, with a 15% growth reported last year [42][44] - 3D Systems is leveraging its metal printing technology for applications in advanced weaponry and shipbuilding [46][47] - The company has established a joint venture in Saudi Arabia to support local manufacturing for defense systems [55] Financial Performance and Strategy - The company has maintained a high level of R&D spending, peaking at over 20% of revenue, to support long-term growth despite short-term profitability challenges [59][61] - Cost reduction efforts have resulted in $50 million in annualized savings, with plans for further optimization [60][63] - The balance sheet has been strengthened, with most debt not due until 2030, positioning the company for future growth [64][65] Future Outlook - 3D Systems is optimistic about the long-term growth potential of 3D printing technology, expecting to see benefits from its investments as the market stabilizes [66][67] - The company aims to capture significant market share in the denture and orthopedic markets, with new product launches anticipated to drive revenue growth in 2026 and beyond [56][58] Additional Insights - The company emphasizes the importance of maintaining strategic investments in technology while managing costs effectively [61][62] - The management believes that the disruptive nature of 3D printing will lead to outsized growth in the long term, rewarding those who have focused on core business strengths during challenging times [66][67]